开发和评估一种基于免疫信息学的多疫苗,用于对抗Acinetobacter baumannii感染
Sean Jeffreys1, Megan P Tompkins1, Jadelynn Aki1
1Department of Molecular Microbiology and Immunology, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Vaccines
|April 27, 2024
概括
一种新型疫苗,AMEV2,是使用免疫信息学设计的,以向多药耐药的Acinetobacter baumannii. 接种疫苗的小鼠显示出对感染的保护,突出了对这种危险病原体的有希望的策略.
科学领域:
- 传染性疾病 传染性疾病
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 多种耐药性 (MDR) Acinetobacter baumannii是医院获得感染的重要原因之一.
- 它的环境持久性,毒性和有限的治疗选择导致高死亡率和医疗保健成本.
- 预防性疫苗接种为敏感人群提供了一个理想的干预策略.
研究的目的:
- 使用免疫信息学设计和评估一种针对MDR Acinetobacter baumannii的新型多表位疫苗.
- 在小鼠模型中评估开发的疫苗的免疫性和保护功效.
主要方法:
- 免疫信息学被用来识别来自A. baumannii毒性蛋白的B细胞和T细胞表位.
- 设计了一种多表位疫苗结构 (AMEV2),包括A. baumannii thioredoxin A和五个抗原.
- 通过免疫和挑战研究,在小鼠中评估了疫苗的免疫性和保护作用.
主要成果:
- 来自受感染小鼠的抗血清与重组AMEV2 (rAMEV2) 反应.
- 用rAMEV2免疫接种诱导了高抗体标位和Th2免疫反应 (增加IL-4分泌囊细胞).
- 接种AMEV2免疫的小鼠被保护免受致命的鼻内挑战,使用高病毒性A. baumannii菌株,显示细菌负担降低.
结论:
- 免疫信息学是设计针对具有挑战性的病原体的疫苗的有效方法.
- 开发的AMEV2疫苗显示出显著的免疫性和对MDR Acinetobacter baumannii的保护性有效性.
- 这项研究提供了一个有前途的疫苗策略,以打击MDR病原体的兴起.
相关概念视频
Vaccinations
Overview
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...


